Financial News
Press Releases about Lexaria Bioscience Corp WT
Via AccessWire
Lexaria Provides Update on Human Nicotine Study NIC-H22-1
April 12, 2022
Via AccessWire
Via AccessWire
Lexaria Begins DehydraTECH-CBD Epilepsy Research Program
March 15, 2022
Via AccessWire
Lexaria Granted Important New Oral Nicotine Patent
March 08, 2022
Via AccessWire
Topics
Intellectual Property
Exposures
Intellectual Property
Via AccessWire
Lexaria Provides Annual Letter From the CEO
January 27, 2022
Via AccessWire
Lexaria Comments on Study Examining Cannabinoids and SARS-CoV-2
January 18, 2022
Via AccessWire
Lexaria Enters One-Year Media Outreach Agreement with SRAX, Inc.
December 16, 2021
Via AccessWire
Lexaria's Clinical Hypertension Study HYPER-H21-3 Nears Completion
December 14, 2021
Via AccessWire
Lexaria's DehydraTECHTM-CBD Reduces Arterial Stiffness, Results Confirmed in Human Clinical Study HYPER-H21-2
December 08, 2021
Via AccessWire
Topics
Intellectual Property
Exposures
Intellectual Property
Lexaria Announces Ambitious New Hypertension Study HYPER-H21-4
November 03, 2021
Via AccessWire
Topics
Intellectual Property
Exposures
Intellectual Property
Lexaria Announces R&D Program to Compare First and Only FDA-Approved Prescription Cannabidiol
November 01, 2021
Via AccessWire
Topics
Intellectual Property
Exposures
Intellectual Property
CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Announces Impressive Findings of Oral THC Absorption Study
October 13, 2021
Via CannabisNewsWire
Topics
Cannabis
Exposures
Cannabis
Lexaria's Technology Proven to Deliver Oral THC More Effectively
October 13, 2021
Via AccessWire
Lexaria Oral Nicotine Study NIC-A21-1 Delivers Outstanding Results
October 05, 2021
Via AccessWire
Topics
Intellectual Property
Exposures
Intellectual Property
Lexaria to Present at the H.C. Wainwright 23rd Annual Global Investment Conference
September 09, 2021
Via AccessWire
Topics
Intellectual Property
Exposures
Intellectual Property
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.